Chickenpox vaccination for all children – lessons for the future of adult immunisation

24 Sep, 2025

ILC’s Chief Executive, David Sinclair, looks at progress made on childhood vaccinations and what lessons there might be for immunisation across the life course.

The UK Government has announced that from January 2026, all children in England will be routinely vaccinated against chickenpox as part of a combined measles, mumps, rubella and varicella (MMRV) jab. This is the first addition to the NHS childhood vaccination schedule since 2015 and will protect around half a million children each year.

This decision marks progress in three important ways.

A success rooted in innovation in adult vaccines
For years, one of the main concerns about introducing a universal chickenpox programme was its potential knock-on effect on shingles rates in older adults. The theory was that adults who had previously had chickenpox were “naturally boosted” by re-exposure to the virus, helping keep shingles at bay. Reducing the circulation of chickenpox could, it was feared, remove this protection.

Advances in the shingles vaccine have helped address this concern. We now have an effective, widely available vaccine for shingles, meaning that we can protect adults through vaccination. In other words, innovation in adult vaccines has paved the way for progress in childhood immunisation.

Recognising the economic as well as health benefits
This decision was made not just on health grounds, but also for its economic impact. Chickenpox costs the UK an estimated £24 million in lost productivity each year as parents take time off work to care for sick children, on top of £15 million in NHS treatment costs. By preventing illness, the new programme will keep more parents in work and children in school or nursery.

It is encouraging to see decision-makers factoring in productivity. But in future, we must go further. The value of better health is not limited to paid work – healthier people are also more able to volunteer, care for relatives, and contribute to their communities. These non-financial benefits must be fully accounted for in policy decisions.

Building on momentum to strengthen adult vaccination
The success of the shingles vaccine in unlocking this decision should remind us of the importance of adult immunisation more broadly. At present, eligibility for shingles vaccination remains narrow. To maximise benefits, we need to increase uptake among those already eligible and consider extending access to more age groups.

Research by the Office of Health Economics shows that every £1 invested in adult vaccination generates a £19 return to the wider economy. But that return only comes if we actually invest the £1. Finance ministries, not just health departments, need to recognise vaccination as an economic growth strategy, not simply a cost.

As the chickenpox rollout begins, the challenge is to apply these lessons across the life course – harnessing innovation, recognising the full value of health, and ensuring all adults have access to the vaccines that can keep them well.

What happens next
The rollout of the chickenpox vaccination will have long-term benefits for people of all ages. Inoculation will help protect younger age groups, while a reduction in chickenpox cases will support adult populations, particularly those clinically at-risk and older adults, who are more susceptible to infectious diseases.

ILC’s Supporting our systems project aims to highlight the impact of vaccine-preventable diseases on older adult populations and why healthy ageing strategies and vaccination are crucial to support those living with weaker immune systems. The chickenpox vaccination programme in England is a clear example of how governments and policymakers can implement health strategies that extend beyond their intended population group and support the wider healthcare environment.

And it’s not just chickenpox vaccination in England that’s important: vaccinations against COVID-19, influenza, pneumococcal disease and RSV are crucial to prevent respiratory infections. Ahead of the seasonal influenza campaign, ILC will be in Brussels on 15 October along with European colleagues to discuss how to forge a comprehensive EU framework for respiratory infection prevention. We’ll also be in Brussels to launch our Supporting our systems report on 6 November, and what policymakers must do to strengthen immunisation programmes in the wake of an ageing European population with waning immune function.

Declaration: ILC has used AI tools to check spelling, punctuation and grammar and to improve the flow of this article.

David Sinclair

ILC's Chief Executive

 

David Sinclair, ILC Chief Executive

David has worked in policy and research on ageing and demographic change for over 20 years. He has a particular interest in older consumers, active ageing, financial services, adult vaccination, and the role of technology in an ageing society. He has a strong knowledge of UK and global ageing society issues, from healthcare to pensions and housing to transport.

Prior to joining the ILC, David worked as Head of Policy at Help the Aged and variously for environmental and disability organisations in policy and public affairs functions. His other experience includes working as a VSO volunteer in Romania, for a Member of Parliament, and with backbench committees.